Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life Science Start-Ups: Tech Transfer Deals, April 2014

This article was originally published in Start Up

Executive Summary

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2014.

You may also be interested in...



Deals In Depth: July 2021

Four $2bn+ alliances were penned in July. Topping the list was a potential $2.4bn deal between Arvinas and Pfizer under which the Big Pharma received worldwide co-exclusive rights to develop and commercialize products containing Arvinas’ ARV-471. ARV-471 is in a Phase II dose expansion clinical trial for the treatment of patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Preclinical and early clinical data for ARV-471 as a single agent and in combination with Ibrance was a key contributor in Pfizer’s decision to partner with Arvinas.

Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021

During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.

Dealmaking Quarterly Statistics, Q2 2021

During Q2, biopharma merger and acquisition value reached $34.7bn and drew in $33bn in potential deal value from alliances. Device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel